CeriBell (NASDAQ:CBLL) Coverage Initiated by Analysts at Canaccord Genuity Group

Canaccord Genuity Group assumed coverage on shares of CeriBell (NASDAQ:CBLL) in a report released on Tuesday, MarketBeat.com reports. The firm issued a buy rating and a $30.00 price objective on the stock.

Other equities research analysts also recently issued reports about the stock. William Blair started coverage on shares of CeriBell in a research report on Tuesday. They set an “outperform” rating on the stock. JPMorgan Chase & Co. began coverage on CeriBell in a report on Tuesday. They issued an “overweight” rating and a $32.00 target price on the stock. Bank of America initiated coverage on shares of CeriBell in a research report on Tuesday. They issued a “buy” rating and a $32.00 price target on the stock. TD Cowen initiated coverage on shares of CeriBell in a research note on Tuesday. They set a “buy” rating and a $31.00 target price for the company. Finally, Canaccord Genuity Group began coverage on shares of CeriBell in a research report on Tuesday. They set a “buy” rating and a $30.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $31.00.

CeriBell Stock Up 2.7 %

Shares of CBLL stock opened at $26.96 on Tuesday. CeriBell has a 12 month low of $23.00 and a 12 month high of $27.71.

About CeriBell

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.